Oncology Research Editorial Office

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.090481 - 13 August 2026

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.090479 - 13 August 2026

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.090478 - 13 August 2026

Abstract This article has no abstract. More >

Yida Wang^1,#, Haiyue You^2,#, Jingyi Gao^3,#, Feng Zhang¹, Xin Ning², Xinfeng Yang², Zhiwen Qian¹, Ying Jiang², Lu Liu², Danping Wu², Yanfang Gu^1,2,*, Daozhen Chen^1,2,*, Yan Zhang^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085967 - 13 August 2026

Abstract Triple-negative breast cancer (TNBC) is characterized by marked metabolic plasticity, spatial heterogeneity, and therapy-induced adaptive remodeling. However, TNBC metabolism is often discussed as isolated pathways, making it difficult to link metabolic rewiring to immune exclusion, drug-tolerant persister cells, and treatment windows. Here, we propose a functional metabolic operating-state framework to organize recurrent adaptive programs in TNBC. Importantly, the S1–S5 framework is not a clinically validated subtype classification, but a set of coexisting and reversible operating states shaped by microenvironmental and therapeutic pressures. S1 represents a glycolysis–lactate/acidosis barrier; S2 denotes fatty acid oxidation (FAO)/oxidative phosphorylation (OXPHOS)-supported… More > Graphic Abstract

Iseult M. Browne^1,2, Susanna Slater¹, Myrto Kastrisiou¹, Mae Alghawas¹, Edward Phillips¹, Mark Beresford³, Stephen R. D. Johnston¹, Zoe Kemp¹, Emma Kipps¹, Marina Parton¹, Nicholas C. Turner^1,2, Alicia F. C. Okines^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085356 - 13 August 2026

Abstract Background: Adenoid cystic carcinoma (ACC) of the breast is a rare triple-negative malignancy with an indolent clinical course distinct from conventional triple-negative breast cancer (TNBC). Optimal management remains undefined due to limited prospective data. This study aimed to characterise the clinicopathological features, treatment patterns, and long-term outcomes of breast ACC at a high-volume specialist centre, contributing real-world evidence to inform management in the absence of prospective trial data. Methods: A single-institution retrospective cohort study was conducted of 24 patients with histopathologically confirmed breast ACC treated at The Royal Marsden NHS Foundation Trust between 2000 and… More >

Shih-Wei Chiang^1,2, Ming-Cheng Chen^2,3, Chang-Lin Lin², Yi-Lin Huang², Feng-Fan Chiang^2,4,*, Shun-Fa Yang^1,5,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085229 - 13 August 2026

Abstract Background: Anti-EGFR therapy is widely used as first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC), particularly in patients with left-sided tumors. In liver-limited disease, maximizing tumor shrinkage may facilitate conversion to resectability; however, comparative real-world evidence among panitumumab, cetuximab, and bevacizumab remains limited. This study aimed to compare the clinical outcomes of these biologic agents in patients with RAS wild-type mCRC. Methods: We retrospectively analyzed 241 patients with RAS wild-type mCRC treated with first-line chemotherapy plus panitumumab (n = 76), cetuximab (n = 80), or bevacizumab (n = 85) between 2016 and 2024. Outcomes included depth of response… More >

Danning Zhao, Qin Liu^*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084736 - 13 August 2026

Abstract Cervical cancer, particularly its advanced stages, requires novel therapeutic paradigms. Cellular immunotherapy exploits the constitutive expression of HPV E6/E7 oncoproteins as near-ideal tumor-specific antigens. This review systematically evaluates four principal platforms under investigation: tumor-infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR-T cells, and CAR-NK cells. We critically analyze the preclinical rationale, clinical trial landscape, safety considerations, and manufacturing challenges for each modality. TIL therapy has achieved durable complete responses and an FDA Breakthrough Therapy designation. TCR-T cells enable precise targeting of intracellular viral epitopes but are HLA-restricted. CAR-T cells offer potent, MHC-independent recognition, yet face on-target/off-tumor More >

Liang Chen¹, Yitong Yuchi², Qian Zhu^3,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084411 - 13 August 2026

Abstract Intraductal Papillary Mucinous Neoplasm (IPMN) is a major precancerous lesion of pancreatic ductal adenocarcinoma. Accurate risk stratification of IPMN is key to preventing and controlling pancreatic cancer. At present, clinicians mainly grade IPMN following the Kyoto consensus guidelines, together with imaging examinations and traditional serum biomarkers like CA19-9 and CEA. This review unveils the latest research progress of non-invasive blood biomarkers for the grading of IPMN, including the diagnostic performance, molecular mechanisms, and current clinical translation of several types of markers. ApoAII has already been applied in clinical practice, and miRNA combinations, circulating cell-free DNA… More >

Chenchen Wang^1,2, Mingzhu Huang^1,2, Wenhua Li^1,2, Xuedan Sheng^1,2, Xiaoying Zhao^1,2, Xiaodong Zhu^1,2, Zhiyu Chen^1,2, Zhe Zhang^1,2, Haiming Li^2,3, Weijian Guo^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084378 - 13 August 2026

Abstract Background: Patients with refractory metastatic colorectal cancer (mCRC) face limited treatment options after failure of standard therapies. This single-arm, phase II study aimed to evaluate the efficacy and safety of rechallenge strategies using previously effective regimens in late-line mCRC. Methods: Patients who progressed after ≥2 lines of prior chemotherapy, with a prior progression-free survival (PFS) ≥4 months and a ≥4-month treatment-free interval on that regimen were enrolled. Patients received rechallenge chemotherapy (oxaliplatin-, irinotecan-, or raltitrexed-based) with or without targeted agents (bevacizumab or cetuximab). Primary endpoint was investigator-assessed PFS. Secondary endpoints included objective response rate (ORR), disease… More >

Chun-Nun Chao^1,2, Chiung-Yao Fang^2,3, Chia-Hsin Hou¹, Jen-Tsung Yang^4,5, Yu-Ping Wu^4,6, Jui-Chieh Chen^6,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083962 - 13 August 2026

Abstract Objectives: Temozolomide (TMZ) resistance remains a major challenge in glioblastoma (GBM) treatment. This study investigated the role of miR-152-3p and its downstream target, transforming growth factor-α (TGF-α), in regulating TMZ sensitivity in GBM. Methods: Public GEO and CGGA datasets were analyzed to evaluate the expression and prognostic significance of miR-152-3p. TMZ-resistant GBM cell lines (U87MGR and DBTRG-05MGR) were established by continuous TMZ exposure. Gain- and loss-of-function experiments were performed using miR-152-3p mimics and inhibitors. Cell viability, apoptosis, and TGF-α expression were assessed by MTT, qRT-PCR, and Western blot analyses. Results: miR-152-3p expression was significantly decreased in recurrent… More >